Skip to main navigation Skip to search Skip to main content

Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes

  • Kamila Urbańczyk*
  • , Sonja Guntschnig
  • , Vasilis Antoniadis
  • , Slaven Falamic
  • , Tijana Kovacevic
  • , Marta Kurczewska-Michalak
  • , Branislava Miljković
  • , Anna Olearova
  • , Inese Sviestiņa
  • , Attila Szucs
  • , Konstantin Tachkov
  • , Zita Tiszai
  • , Daisy Volmer
  • , Anna Wiela-Hojeńska
  • , Daniela Fialova
  • , Jiri Vlcek
  • , Matej Stuhec
  • , Anita Hogg
  • , Michael Scott
  • , Derek Stewart
  • Alpana Mair, Silvia Ravera, François Xavier Lery, Przemysław Kardas
*Corresponding author for this work
    • Regional Specialist Hospital in Wroclaw
    • Wrocław Medical University
    • Tauernklinikum Zell am See
    • Ulster University
    • Independent Expert
    • University of Banja Luka
    • University Clinical Center of Republic of Srpska
    • Medical University of Łódź
    • University of Belgrade
    • University Hospital in Bratislava
    • Children's Clinical University Hospital
    • National Institute of Oncology
    • Medical University Sofia
    • Bajcsy-Zsilinszky Hospital
    • University of Tartu
    • Charles University
    • Ormoz Psychiatric Hospital
    • University of Maribor
    • Northern Health and Social Care Trust
    • European Society of Clinical Pharmacy
    • Qatar University
    • Scottish Government
    • Council of Europe

    Research output: Contribution to journalArticlepeer-review

    37 Citations (Scopus)

    Abstract

    Clinical pharmacy as an area of practice, education and research started developing around the 1960s when pharmacists across the globe gradually identified the need to focus more on ensuring the appropriate use of medicines to improve patient outcomes rather than being engaged in manufacturing and supply. Since that time numerous studies have shown the positive impact of clinical pharmacy services (CPS). The need for wider adoption of CPS worldwide becomes urgent, as the global population ages, and the prevalence of polypharmacy as well as shortage of healthcare professionals is rising. At the same time, there is great pressure to provide both high-quality and cost-effective health services. All these challenges urgently require the adoption of a new paradigm of healthcare system architecture. One of the most appropriate answers to these challenges is to increase the utilization of the potential of highly educated and skilled professionals widely available in these countries, i.e., pharmacists, who are well positioned to prevent and manage drug-related problems together with ensuring safe and effective use of medications with further care relating to medication adherence. Unfortunately, CPS are still underdeveloped and underutilized in some parts of Europe, namely, in most of the Central and Eastern European (CEE) countries. This paper reviews current situation of CPS development in CEE countries and the prospects for the future of CPS in that region.

    Original languageEnglish
    Article number1244151
    Pages (from-to)1-16
    JournalFrontiers in Pharmacology
    Volume14
    DOIs
    Publication statusPublished - 2023

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 9 - Industry, Innovation, and Infrastructure
      SDG 9 Industry, Innovation, and Infrastructure

    Keywords

    • clinical pharmacy
    • cost-effective treatment
    • drug safety
    • drug utilization
    • health policy
    • medication adherence
    • medication errors
    • polypharmacy

    Fingerprint

    Dive into the research topics of 'Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes'. Together they form a unique fingerprint.

    Cite this